Cervical Cancer Deaths Fall to Zero in Young Women Given Vaccine
- Cervical cancer deaths fall to zero in young women given HPV vaccine
- MUSC researchers attribute decline to HPV vaccination
- Study published in JAMA shows significant reduction in cancer risk
- HPV vaccine recommended for all 11- to 12-year-old girls and boys
- Vaccine effectiveness highest when given before HPV infection
Cervical cancer deaths have plunged dramatically among women under age 25, and researchers at MUSC Hollings Cancer Center believe this is likely due to HPV vaccination.
Officials said the study, published in JAMA, is the first to suggest the impact of HPV vaccination.
The HPV vaccine is the most advantageous when given before the infection.
- 11- to 12-year-old girls and boys are recommended to get vaccinated.
- The vaccine holds the promise to safely prevent many kinds of cancers attributable to HPV.
Vaccine Effectiveness and Access
The HPV vaccine is erasing cancer, with more than a decade of data showing its effectiveness.
Sources confirmed that the vaccine covers more strains of HPV, the dosage has dropped from three to two shots, and the cost is fully covered by private insurance and public programs.
Meanwhile, experts said that barriers such as limited health care access, insurance status, vaccine hesitancy, limited public education, stigma, and cost diminish the impact of the vaccine.
In contrast, the vaccine was originally recommended only for girls, but now it is recommended for all people through 26 years if they did not get vaccinated when they were younger.
Real-World Effectiveness of HPV Vaccination
Real-world effectiveness of human papillomavirus vaccination has been studied, and the results show that the vaccine is highly effective in preventing cervical cancer.
Government sources said that the vaccine efficacy and effectiveness of different vaccine types in women under 26 years is summarized in Table 2.
However, witnesses said that some women are still not getting vaccinated due to various barriers.
Despite this, the HPV vaccine has been shown to be highly effective in preventing genital warts in young women.
Historical Context and Impact
The HPV vaccine was introduced to the U.S. in 2006, and since then, it has been shown to be highly effective in preventing cervical cancer.
Historically, cervical cancer has been a major cause of death among women, but with the introduction of the HPV vaccine, the incidence of the disease has decreased significantly.
In 2014, most vaccinations given were the quadrivalent type, which targets oncogenic HPV types 6/11/16/18.
The quadrivalent HPV vaccine shows excellent efficacy against genital warts in young women.
Human Impact of HPV Vaccine
The HPV vaccine has had a significant impact on the lives of many women, saving them from the risk of cervical cancer.
Officials said that the vaccine has been shown to be highly effective in preventing cervical cancer, and it is recommended for all 11- to 12-year-old girls and boys.
Meanwhile, experts said that the vaccine is also effective in preventing other types of cancer, such as anal and oropharyngeal cancer.
In contrast, some women are still not getting vaccinated due to various barriers, but the HPV vaccine has been shown to be a highly effective tool in the fight against cervical cancer.